Lodestone Biomedical INC. logo

Lodestone Biomedical

About

Lodestone's biosensor and reader opens the door for a broad spectrum of longitudinal in vivo assays in the tumor microenvironment. Our small-animal system and in vivo assay technology accelerates cancer research. Lodestone's products are for research use only.

Highlights

$12.5M
CF Valuation
$228K
Total Raised
$957.2K
Revenue
1
Employees

Indicators

Profit Margin
-6.2%
(31.7%)
2022: -37.9%
Current Ratio
26.51
(116.9%)
2022: 12.22

Revenue Growth